Bioatla, INC 8-K filings

BioAtla, Inc. held its Annual Meeting of Stockholders on July 16, 2026, where shareholders approved the election of two directors, ratified the appointment of Ernst & Young LLP as independent auditor, and approved executive compensation.

BioAtla, Inc. has filed a certificate of merger to execute a 1-for-50 reverse stock split effective April 6, 2026.

BioAtla's stockholders approved a merger and a 1-for-50 reverse stock split, while the company also implemented retention bonuses for key executives following a year without performance bonuses.

BioAtla announced a significant workforce reduction and a formal process to explore strategic options amidst Nasdaq delisting review and revised investment plans.

BioAtla, Inc. announced that Nasdaq's Listing Council has called for a review of its delisting determination, staying the suspension of trading pending the outcome.

BioAtla, Inc. received a delisting determination from Nasdaq, with trading suspension set for February 10, 2026, due to non-compliance with listing rules.

BioAtla faces Nasdaq delisting after a policy change on super-voting stock, prompting a new 1-for-50 reverse stock split via merger and securing a $5 million investment.

BioAtla, Inc. issued a Super-Voting Share to its CEO, Jay M. Short, Ph.D., granting him significant voting power on specific proposals, including a pending reverse stock split, after failing to secure sufficient shareholder votes.

BioAtla forms a new subsidiary and secures $40 million from Inversagen AI to advance its Ozuriftamab Vedotin (Oz-V) cancer therapeutic into a Phase 3 clinical trial for oropharyngeal squamous cell carcinoma.

BioAtla's special stockholder meeting approved a stock issuance but adjourned to solicit more votes for a proposed reverse stock split.

BioAtla, Inc. has entered into two new financing agreements, a $7.5 million Pre-Paid Advance and a $15.0 million Standby Equity Purchase Agreement, to bolster its capital.

BioAtla, Inc. announced its third quarter 2025 financial results, highlighted FDA alignment for its Phase 3 Oz-V trial, and is in advanced stages to finalize a strategic transaction.

BioAtla, Inc. has received conditional approval from the Nasdaq Hearing Panel to maintain its listing, requiring transfer to The Nasdaq Capital Market and compliance with equity and bid price requirements by early 2026.

BioAtla, Inc. announced its second quarter 2025 financial results, showcasing reduced operating expenses and promising clinical progress for its lead oncology programs, BA3182 and Ozuriftamab vedotin.

BioAtla, Inc. announced the approval of its 2025 Corporate Bonus Plan for executive officers and reported the voting results from its Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

BioAtla, Inc. received a notice from Nasdaq regarding non-compliance with minimum stockholders' equity requirements, putting its listing status at risk.

BioAtla announces first quarter 2025 financial results and highlights positive clinical progress across its CAB platform, including encouraging survival data for Mec-V and antitumor activity for Oz-V.

BioAtla reports financial results for Q4 and full year 2024, highlights clinical progress, and announces cost-reduction measures including a workforce reduction.

BioAtla's executives, including the CFO, CMO, and CEO, received cash bonuses and restricted stock units (RSUs) in recognition of the company's achievement of clinical development, research and development, and business objectives in 2024.

BioAtla, Inc. received a notification from Nasdaq stating that it is not in compliance with the minimum bid price requirement, giving the company until August 5, 2025, to regain compliance.

BioAtla, Inc. has announced a registered direct offering expected to generate $9.2 million to fund its mid-stage clinical programs.

BioAtla is progressing its clinical-stage pipeline of Conditionally Active Biologics (CABs) for cancer therapy, with multiple clinical readouts expected through 2025 and into 2026.

BioAtla announced encouraging clinical trial results for its cancer therapies and a license agreement that extends its cash runway into early 2026.

BioAtla has granted Context Therapeutics an exclusive worldwide license to develop and commercialize two bispecific antibodies, including BA3362, for a potential total of $133.5 million plus royalties.

BioAtla reported its Q2 2024 financial results, highlighted clinical progress, and received Fast Track Designation for ozuriftamab vedotin.

BioAtla, Inc. held its annual meeting on June 13, 2024, where stockholders elected a director, ratified the appointment of an auditor, and approved executive compensation on an advisory basis.

BioAtla has settled a shareholder class action lawsuit regarding amended bylaws by agreeing to pay $350,000 in legal fees and expenses.

BioAtla announced its first quarter 2024 financial results and provided updates on its clinical programs, highlighting positive responses and manageable safety profiles for several key drug candidates.

BioAtla, Inc. has amended its bylaws, modifying advance notice requirements for stockholder nominations and business proposals.

BioAtla reported its Q4 and full year 2023 financial results, highlighting progress in its clinical programs and upcoming data readouts.